Bepridil, which is clinically useful in the treatment of arrhythmias, has been reported to inhibit sarcolemmal ATP-sensitive K ϩ (sarcK ATP ) channels. However, the effect of bepridil on mitochondrial ATP-sensitive K ϩ (mitoK ATP ) channels remains unclear. The objective of the present study was to determine whether bepridil activates mitoK ATP channels and confers cardioprotection. SarcK ATP channels composed of Kir6.2ϩSUR2A in human embryonic kidney (HEK) 293 cells were examined using the patch-clamp technique. Flavoprotein fluorescence in guinea pig ventricular cells and matrix volume in isolated rat heart mitochondria were measured to assay mitoK ATP channel activity. Mitochondrial Ca 2ϩ concentration ([Ca 2ϩ ] m ) was measured by loading cells with rhod-2 fluorescence. Coronaryperfused guinea pig ventricular muscles were subjected to 35-min no-flow ischemia followed by 60-min reperfusion. Bepridil (10 M) completely inhibited the pinacidil-induced Kir6.2ϩSUR2A channel current expressed in HEK 293 cells. Bepridil reversibly oxidized the flavoprotein and increased mitochondrial matrix volume in a concentration-dependent manner. Furthermore, bepridil significantly attenuated the ouabaininduced increase of [Ca 2ϩ ] m . Pretreatment with bepridil for 5 min before ischemia improved the recovery of developed tension measured after 60 min of reperfusion. These effects of bepridil were abolished by the mitoK ATP channel blocker 5-hydroxydecanoate (500 M) and by the nonselective K ATP channel blocker glisoxepide (10 M). Our results indicate that bepridil is an opener of mitoK ATP channels but an inhibitor of sarcK ATP channels and exerts a direct cardioprotective effect on native cardiac myocytes. This is the first report of a unique modulator of K ATP channels; bepridil would be expected to mitigate ischemic injury while blunting arrhythmias.
Kir6.2ϩSUR2A channel current expressed in HEK 293 cells. Bepridil reversibly oxidized the flavoprotein and increased mitochondrial matrix volume in a concentration-dependent manner. Furthermore, bepridil significantly attenuated the ouabaininduced increase of [Ca 2ϩ ] m . Pretreatment with bepridil for 5 min before ischemia improved the recovery of developed tension measured after 60 min of reperfusion. These effects of bepridil were abolished by the mitoK ATP channel blocker 5-hydroxydecanoate (500 M) and by the nonselective K ATP channel blocker glisoxepide (10 M). Our results indicate that bepridil is an opener of mitoK ATP channels but an inhibitor of sarcK ATP channels and exerts a direct cardioprotective effect on native cardiac myocytes. This is the first report of a unique modulator of K ATP channels; bepridil would be expected to mitigate ischemic injury while blunting arrhythmias.
Cardiac ATP-sensitive K ϩ (K ATP ) channels are present both in sarcolemmal plasma membrane (sarcK ATP channel) and in mitochondrial inner membrane (mitoK ATP channel) (Noma, 1983; Garlid et al., 1996) . Although the relative roles of the mitoK ATP channels and sarcK ATP channels remain elusive, it is generally accepted that opening of mitoK ATP channels is cardioprotective (Garlid et al., 1997; Liu et al., 1998 , O'Rourke, 2000 Sato and Marbá n, 2000) , whereas opening of sarcK ATP channels is rather arrhythmogenic (Chi et at., 1990; Fischbach et al., 2004) . Recently, the IONA study has reported that nicorandil, which primarily activates mitoK ATP channel (Sato et al., 2000a) , reduced the incidence of major cardiovascular events in patients with chronic stable angina (IONA Study Group, 2002) . This favorable outcome in IONA study has stimulated interest in the development of newer mitoK ATP channel openers. At present, however, there are no mitoK ATP channel openers available that are suitable for clinical use other than nicorandil.
Cardiac sarcK ATP channels are hetero-octamers of four pore-forming Kir6.2 and four SUR2A sulfonylurea receptors (Seino, 1999) , whereas the molecular identity of mitoK ATP channels remains unknown (Ardehali et al., 2004) . Besides sulfonylureas, class I antiarrhythmic drugs have been shown to inhibit the sarcK ATP channels (Undrovinas et al., 1990; Wu et al., 1992) . More recently, we have reported that amiodarone inhibits sarcK ATP but not mitoK ATP channel in guinea pig ventricular cells (Sato et al., 2003) . Bepridil, a class IV antiarrhythmic drug, was originally developed as an antianginal drug with calcium channel-blocking effects, but the drug has multiple ion channel-blocking effects (Yatani et al., 1986; Cohen et al., 1992; Gill et al., 1992; Wang et al., 1999) similar to amiodarone and is expected to be effective for the termination of arrhythmias. Li et al. (1999) have previously demonstrated that bepridil inhibits sarcK ATP channel activity in guinea pig ventricular myocytes. However, it still remains unclear whether or not bepridil modulates the cardiac mitoK ATP channel activity. The results presented here show that bepridil is a mixed mitoK ATP channel opener/ sarcK ATP channel blocker and confers cardioprotection.
Materials and Methods
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (National Institutes of Health publication 85-23, revised 1985) .
Functional Expression of SarcK ATP Channels and Electrophysiology. Human embryonic kidney (HEK) 293 cells were transiently cotransfected with pcDNA3.1 vectors (Invitrogen, Carlsbad, CA) containing the coding sequence of cloned cDNAs of rat SUR2A and human Kir6.2 subunits (both gifts of Dr. S. Seino, Kobe University, Kobe, Japan) and pEGFP-C1 (BD Biosciences, San Jose, CA) using LipofectAMINE (Invitrogen). The cells that expressed green fluorescent protein were identified by fluorescence microscopy and were used for electrophysiology. Electrophysiological recordings were made 18 to 48 h after transfection. Membrane currents were recorded using the whole-cell patch configuration, with bath solution containing 143 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 0.33 mM NaH 2 PO 4 , 0.5 mM MgCl 2 , 5.5 mM glucose, and 5 mM HEPES, adjusted to pH 7.4 with NaOH. The pipette solution contained 110 mM K-aspartate, 20 mM KCl, 1.4 mM CaCl 2 , 1 mM MgCl 2 , 10 mM EGTA, 5 mM HEPES, 1 mM phosphocreatinine, and 1 mM K 2 -ATP, pH 7.2, titrated with KOH. Junction potential was corrected. A ramp voltage command from Ϫ100 to ϩ50 mV was applied over 100 ms every 5 s, from a holding potential of Ϫ40 mV. The current signals were filtered at 3 kHz with a digital Gaussian filter and digitized at 2 kHz for data analysis with pClamp software (Molecular Devices, Sunnyvale, CA). The experiments were performed at 36°C.
Cell Isolation. Single ventricular myocytes of the guinea pig hearts were obtained by enzymatic dissociation, as previously described (Tohse et al., 1992) . Once isolated, the cells were suspended in Dulbecco's modified Eagle's medium containing 10% fetal calf serum at room temperature until use. The cells used in the present experiments had a regular shape with clear cross-striation.
Flavoprotein Fluorescence Measurement. To index mitoK ATP channel activity, flavoprotein fluorescence was measured by a modification of method described by Sato et al. (1998) . The cells were superfused with glucose-free bath solution containing 143 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 0.33 mM NaH 2 PO 4 , 0.5 mM MgCl 2 , and 5 mM HEPES, adjusted to pH 7.4 with NaOH. Flavoprotein fluorescence was excited at 480 nm (for 200 ms every 10 s) and emitted at 520 nm. At the end of each experiment, cells were exposed to the mitochondrial uncoupler 2,4-dinitrophenol (DNP; 100 M) to obtain maximal flavoprotein oxidation. These experiments were performed at room temperature (Ϸ22°C). Emitted fluorescence was monitored with a cooled charge-coupled device digital camera (Hamamatsu Photonics, C4742-95; Hamamatsu Corporation, Bridgewater, NJ). The imaging of flavoprotein was analyzed for average pixel intensities of regions of interest drawn to include whole cell and expressed as a percentage of the DNP-induced maximal oxidation, using an Aquacosmos image-processing system (Hamamatsu Corporation).
Mitochondrial Isolation and Measurement of Mitochondrial Volume. Mitochondria were isolated from rat heart by differential centrifugation described by Jaburek et al. (1998) . The final mitochondrial pellet was resuspended at 20 mg/ml in 250 mM sucrose and potassium salts of 10 mM HEPES, pH 7.2, and 0.1 mM EGTA. Mitochondria were assayed within 2 h of isolation and kept on ice with constant stirring and free access to O 2 during the experiments. Changes in mitochondrial volume, which accompany net salt transport into mitochondria, were followed using a quantitative light-scattering technique (Beavis et al., 1985) . This technique is based on the principle that reciprocal absorbance of the mitochondrial suspension, when corrected for the extrapolated absorbance at infinite protein concentration, is linearly related to matrix volume within well defined regions, as described in detail by Beavis et al. (1985) . Light-scattering changes of mitochondrial suspensions were followed at 520 nm and 30°C and reported as ␤, defined as:
where P is the protein concentration in the assay, and 1/Aϱ is the reciprocal of the apparent absorbance at infinite protein concentration. The dose-response curve presented herein was obtained from normalized matrix volume values at 120 s, as follows:
where ␤(X) is the light-scattering parameter (an index of mitochondrial matrix volume) measured at 120 s under a given concentration (X) of bepridil. ␤(ATP) and ␤(0) are the measured values at 120 s in the presence and absence of ATP, respectively. The assay medium contained 120 mM KCl, 0.5 mM MgCl 2 , 5 mM phosphate, 10 mM succinate, 0.1 mM EGTA, 0.005 mM rotenone, 0.001 mM oligomycin, and 10 mM HEPES, pH 7.2.
[Ca 2؉ ] m Measurement. The Ca 2ϩ fluorophore rhod-2 was used to measure changes of mitochondrial Ca 2ϩ concentration ([Ca 2ϩ ] m ). For rhod-2 loading, guinea pig ventricular myocytes were plated on uncoated 35-mm Falcon culture dishes with a medium based on a 1:1 mixture of Dulbecco's modified Eagle's medium and HEPES-buffered Tyrode's solution, supplemented with 5% fetal calf serum. Then, cells were loaded with rhod-2 acetoxymethyl ester (10 M) for 120 min at 4°C. After cold loading, cells were incubated for 30 min at 37°C. This two-step cold loading/warm incubation protocol achieves exclusive loading of rhod-2 into the mitochondria (Trollinger et al., 2000) . Cells loaded with rhod-2 were perfused with a HEPES-buffered Tyrode's solution containing 2.7 mM CaCl 2 at 37°C. Rhod-2 fluorescence was excited at 540 nm (for 100 ms), with emission monitored through a 605-nm (55-nm bandpass) barrier filter. The imaging of rhod-2 was analyzed for average pixel intensities of regions of interest drawn to include whole cell, following correction for background, using an Aquacosmos image-processing system (Hamamatsu Corporation).
Coronary-Perfused Right Ventricular Myocardium. The isolated coronary-perfused guinea pig right ventricular free wall was prepared as described previously (Shigematsu et al., 1995) . The preparation was mounted in the recording chamber and pinned to the floor of the chamber. The coronary artery was perfused with oxygenated Tyrode's solution containing 136.7 mM NaCl, 11.9 mM NaHCO 3 , 5.4 mM KCl, 0.42 mM NaH 2 PO 4 , 0.5 mM MgCl 2 , 1.8 mM CaCl 2 , and 11 mM glucose, pH 7.35 to 7.40 (when gassed with 95% O 2 and 5% CO 2 ). The flow rate was maintained at 1.0 Ϯ 0.2 ml/min/g wet weight using a roller pump (MP-3; Tokyo Rikakikai, Tokyo, Japan). The surface of the preparation was superfused with glucosefree hypoxic Tyrode's solution (10 ml/min) to minimize direct O 2 diffusion from the surface of the preparations into the muscles. The composition of the hypoxic Tyrode's solution was the same as above, except that it contained no glucose and was gassed with 95% N 2 and 5% CO 2 . The temperatures of these solutions were maintained at 37 Ϯ 0.5°C. The basal portion of the preparation was stimulated at 3.3 Hz throughout the experiment, and contractile tension was recorded using a force transducer (TB-612T; Nihon Kohden, Tokyo, Japan) connected to the apical end of the preparation. Resting tension was adjusted to obtain the optimal developed tension. The contractile tension was monitored on a multibeam oscilloscope (VC- jpet.aspetjournals.org 9A; Nihon Kohden) and recorded on a multichannel thermal arraycorder (WT-645G; Nihon Kohden).
Experimental Protocol. After equilibration for 60 min, the coronary-perfused ventricular muscle preparations were assigned to the study groups: CONT, the preparations were subjected to 35 min of no-flow ischemia followed by 60 min of reperfusion; BP(1), the preparations were treated for 5 min with 1 M bepridil followed by a 10-min washout before no-flow ischemia; BP(10), the preparations were treated for 5 min with 10 M bepridil followed by a 10-min washout before no-flow ischemia; BP(10)ϩGX, pretreatment with glisoxepide (GX, 10 M) starting 5 min prior to and continued during bepridil (10 M) treatment; and BP(10)ϩ5HD, pretreatment with the mitoK ATP channel blocker 5-hydroxydecanoate (5HD; 500 M) starting 5 min prior to and continued during bepridil (10 M) treatment.
Chemicals. Bepridil was a kind gift from Sankyo Pharmaceutical (Omiya, Japan). Glisoxepide was a kind gift from Aventis (Strasbourg, France). Diazoxide, sodium 5HD, glibenclamide, ouabain, and tetraphenylphosphonium were purchased from Sigma-Aldrich (St. Louis, MO). DNP was purchased from Wako Pure Chemicals (Osaka, Japan). Rhod-2 acetoxymethyl ester was purchased from Molecular Probes (Eugene, OR). Glibenclamide and glisoxepide were dissolved in dimethyl sulfoxide at a concentration of 100 mM. Ouabain, 5HD, and DNP were dissolved in the perfusate.
Data Analysis. Data are presented as mean Ϯ S.E.M., and the number of cells or experiments is shown as n. Intergroup comparisons are made by Student's t test for two groups and by analysis of variance followed by Fisher's post hoc test for multiple groups. A value of p Ͻ 0.05 was regarded as significant.
Results

Effect of Bepridil on Expressed SarcK ATP Channel
Current. Bepridil has been reported to block sarcK ATP channel current in guinea pig ventricular myocytes (Li et al., 1999) . We therefore examined the effect of bepridil on Kir6.2ϩSUR2A (cardiac-type sarcK ATP ) channel current expressed in HEK 293 cells. Figure 1A shows the representative current traces elicited by ramp pulses. Pinacidil (100 M), a nonselective K ATP channel opener (Liu et al., 1998) , evoked an outward current. The pinacidil-induced current was completely suppressed by the subsequent application of bepridil (10 M). As summarized in Fig. 1B , pinacidil significantly increased the membrane current measured at the membrane potential of 0 mV from 0.53 Ϯ 0.22 nA (control, n ϭ 5) to 3.15 Ϯ 1.20 nA (n ϭ 5, p Ͻ 0.01 versus control). Bepridil (10 M) significantly blocked the pinacidil-induced currents to 0.87 Ϯ 0.42 nA (n ϭ 5, p Ͻ 0.01 versus pinacidil). These results indicate that bepridil is a blocker of cardiac sarcK ATP channels.
Effect of Bepridil on Flavoprotein Fluorescence. The effects of bepridil on mitoK ATP channels were evaluated by measuring flavoprotein fluorescence. Figure 2 , A and B, show the time course of flavoprotein fluorescence in a cell exposed to bepridil and/or glisoxepide. Bepridil (1 and 10 M) reversibly oxidized flavoprotein in a concentration-dependent manner ( Fig. 2A) . In the presence of the nonselective K ATP channel blocker glisoxepide (10 M), a second exposure to bepridil (10 M) failed to increase flavoprotein fluorescence (Fig. 2B) . As summarized in Fig. 2C , bepridil at concentrations of 1 and 10 M increased flavoprotein oxidation to 21.7 Ϯ 5.1% (n ϭ 6) and 31.8 Ϯ 3.2% (n ϭ 9) of the DNP value, respectively. The mitoK ATP channel inhibitor 5HD (500 M) significantly inhibited the bepridil (1 and 10 M)-induced flavoprotein oxidation. Furthermore, oxidative effect of 10 M bepridil was blocked both by glisoxepide (10 M) and by tetraphenylphosphonium (0.1 M), a potent inhibitor of mitoK ATP channel (Mironova et al., 2004) . These results indicate that bepridil is an opener of mitoK ATP channels.
Effect of Bepridil on Isolated Heart Mitochondria. To further confirm that bepridil is a potent opener of mitoK ATP channel, the effect of bepridil on mitochondrial matrix swelling was studied. Figure 3A contains representative traces from light-scattering experiments and demonstrates the volume changes due to opening and closing of mitoK ATP channels in rat heart mitochondria. Mitochondrial matrix swelling was inhibited by addition of ATP (0.2 mM) as previously described (Beavis et al., 1985; Jaburek et al., 1998) . Concomitant addition of bepridil (0.3 M) restored matrix volume to control values. 5HD (300 M) prevented changes in mitochondrial matrix volume induced by bepridil. As summarized in Fig. 3B , analysis of the matrix volume steady state at 120 s in the presence of various concentrations of bepridil showed that activation of mitoK ATP channels by bepridil was dosedependent, with ED 50 values of 27.5 Ϯ 2.3 nM.
Effect of Bepridil on Mitochondrial Ca 2؉ Overload. We previously reported that the mitoK ATP channel openers attenuate the mitochondrial Ca 2ϩ overload in ventricular myocytes (Ishida et al., 2001 (Ishida et al., , 2004 . We then examined the effect of bepridil on mitochondrial Ca 2ϩ overload. As summarized in Fig. 4 jpet.aspetjournals.org Downloaded from 7, p Ͻ 0.05), respectively. The effect of bepridil was antagonized both by glisoxepide (10 M, 247.9 Ϯ 21.7% of baseline, n ϭ 7) and by 5HD (500 M, 223.4 Ϯ 15.9% of baseline, n ϭ 7). These results indicate that opening of mitoK ATP channel by bepridil attenuates the ouabain-induced Ca 2ϩ overload in mitochondria.
Effect of Bepridil on Contractile Function during Ischemia/Reperfusion. To test whether bepridil confers cardioprotection in guinea pig hearts, coronary-perfused right ventricular preparations were subjected to 35-min noflow ischemia, followed by 60-min reperfusion. Figure 5 shows the time courses of developed tension during ischemia/ reperfusion. In the control group, the developed tension measured after 60 min of reperfusion was decreased to 24.9 Ϯ 2.2% of preischemic values (n ϭ 5). Pretreatment with 1 and 10 M bepridil prior to ischemia significantly and dose dependently improved the recovery of contractility after 60 min of reperfusion to 48.6 Ϯ 7.4% (n ϭ 5, p Ͻ 0.05) and 60.2 Ϯ 5.2% (n ϭ 5, p Ͻ 0.05), respectively. This cardioprotective effect of bepridil was blocked both by glisoxepide (29.4 Ϯ 2.8%, n ϭ 5, p Ͻ 0.05 versus bepridil alone) and by 5HD (23.4 Ϯ 2.7%, n ϭ 5, p Ͻ 0.05 versus bepridil alone). These results suggest that bepridil confers cardioprotection via activation of mitoK ATP channels.
Discussion
Bepridil Blocks SarcK ATP Channel. A previous study by Li et al. (1999) has provided electrophysiological evidence that bepridil inhibits the sarcK ATP channel activity in guinea pig ventricular myocytes, with apparent IC 50 value of 6.6 to 10.5 M. To confirm these findings in a mammalian expression system, cardiac-type sarcK ATP channel (Kir6.2ϩSUR2A) was expressed in HEK 293 cells. We found that bepridil (10 M) completely inhibited the pinacidil-induced Kir6.2ϩSUR2A channel currents (Fig. 1) , suggesting bepridil is a potent blocker of cardiac sarcK ATP channel. It is generally accepted that the activation of sarcK ATP channels during ischemia shortens action potential duration and refractoriness, which may result in reentrant ventricular arrhythmias (Wilde and Janse, 1994) . Our previous report in Kir6.2-deficient mice, however, has demonstrated that opening of sarcK ATP channels is by no means proarrhythmic and may jpet.aspetjournals.org rather reduce the incidence of arrhythmias (Saito et al., 2005) . Since configuration of action potentials varies from species to species, the relative impact of sarcK ATP channel activation on the development of ischemic arrhythmia may differ between mouse hearts and those of larger mammals. In a dog model of ischemia/reperfusion, nonselective K ATP channel opener pinacidil increased the potential for the development of ventricular fibrillation (Chi et al., 1990) , and the selective sarcK ATP channel blocker HMR 1883 effectively prevented ischemia-induced ventricular fibrillation (Billman et al., 1998; Sato et al., 2000b) . Therefore, sarcK ATP channel blockade by bepridil appears to be effective against ischemic arrhythmias by preventing the action potential shortening.
Bepridil Activates MitoK ATP Channel. To assay the function of mitoK ATP channels in intact cells, we measured flavoprotein fluorescence (Liu et al., 1998; Sato et al., 1998) and found that bepridil oxidized flavoprotein in a concentration-dependent manner (Fig. 2) . These oxidative effects of bepridil were inhibited by 5HD, a potent mitoK ATP channel blocker. However, the method of measuring flavoprotein oxidation has some limitations; an uncoupling effect of drug, without relation to mitoK ATP channel, results in flavoprotein oxidation. In fact, bepridil exerts an uncoupling effect at high concentrations (A. D. T. Costa and K. D. Garlid, unpublished data), in agreement with a previous report (Leblondel and Allain, 1984) . Moreover, it has been claimed that 5HD may be converted to 5HD-CoA (Hanley et al., 2002) . To rule out possible mitoK ATP channel-independent effects of bepridil, we carried out experiments in which several mitoK ATP channel blockers other than 5HD were examined on the bepridilinduced flavoprotein oxidation. Although glibenclamide alone uncouples mitochondria and independently causes flavoprotein oxidation (Hu et al., 1999) , glisoxepide alone did not oxidize flavoprotein, suggesting this sulfonylurea has no uncoupling effect. Glisoxepide significantly inhibited the oxidative effect of bepridil. Furthermore, the potent mitoK ATP channel blocker tetraphenylphosphonium (Mironova et al., 2004) prevented the bepridil-induced flavoprotein oxidation. To further verify that the bepridil-induced flavoprotein oxidation reflects the activation of mitoK ATP channel, we measured the mitochondrial matrix volume, a robust indicator of mitoK ATP channel opening (Beavis et al., 1985; Jaburek et al., 1998) . As in the case of the mitoK ATP channel opener diazoxide (Jaburek et al., 1998) , bepridil increased K ϩ flux and caused mitochondrial swelling (Fig. 3) . Therefore, it is reasonable to assume that bepridil is an opener of mitoK ATP channels.
In isolated mitochondria, matrix swelling could be induced by lower concentrations of bepridil (EC 50 ϭ 27.5 nM). The difference in sensitivity of bepridil in isolated mitochondria compared with intact myocytes, which is common to most pharmacological attempts to correlate mitochondrial ion channels with a response, may be explained by the higher concentration of ATP and diffusional barriers in the intact cells. Whatever this difference is, the effect of bepridil on the mitoK ATP channel would be expected in clinical settings because the therapeutic clinical concentrations were reported to be ϳ3 M (Hollingshead et al., 2000) .
Mechanisms of Cardioprotection. The experimental model of ouabain-induced mitochondrial Ca 2ϩ overload was used in our earlier study, in which we showed that in rat cardiomyocytes, the mitoK ATP channel opener diazoxide attenuated the mitochondrial Ca 2ϩ overload and such effect associated with the depolarization of mitochondrial membrane potential (Ishida et al., 2001 (Ishida et al., , 2004 . The present study demonstrated that bepridil prevented the mitochondrial Ca 2ϩ overload in guinea pig ventricular myocytes (Fig. 4) . Moreover, these effects of bepridil were abolished both by 5HD and by glisoxepide. These results suggest that attenuation of mitochondrial Ca 2ϩ overload might potentially be contributed to the mechanism of cardioprotection afforded by bepridil. Recent study has shown that opening of mitoK ATP channels results in reactive oxygen species formation and acts as trigger mechanisms to preconditioning (Pain et al., 2000; Forbes et al., 2001) . In the present study, we found that brief exposure to bepridil before ischemia significantly improved the postischemic functional recovery (Fig. 5) . These effects of bepridil were again abolished both by 5HD and by glisoxepide. Although we did not examine the effect of reactive oxygen species scavenger, these results suggest that opening of mitoK ATP channels by bepridil acts as a trigger of cardioprotection. Sasaki et al. (2003) reported that MCC-134, a novel vasorelaxing agent, opened sarcK ATP channels but blocked mitoK ATP channels; therefore, the drug abolished cardioprotection in ischemic hearts. In the present study, despite the blockade of sarcK ATP channels, bepridil conferred cardioprotection via opening of mitoK ATP channels. Therefore, the results of studies of both MCC-134 and bepridil support the concept that mitoK ATP rather than sarcK ATP channels are the key players in cardioprotection.
Conclusions
As described above, the selective mitoK ATP channel openers are effective in protecting hearts, whereas the selective sarcK ATP channel blockers are effective in preventing arrhythmias. In the context of this theory, a mixed sarcK ATP channel blocker/mitoK ATP channel agonist may be a perfect modulator of K ATP channels. Unfortunately, a mixed agonist/ blocker MCC-134 has the opposite profile (Sasaki et al., 2003) and may blunt cardioprotection and favor ischemic arrhythmias. The present study demonstrates that bepridil, which has been utilized clinically in arrhythmias, represents the first known mixed mitoK ATP channel opener/sarcK ATP channel blocker. Besides inhibiting sarcK ATP channels, bepridil has been shown to block multiple ion channels (Yatani et al., 1986; Cohen et al., 1992; Gill et al., 1992; Wang et al., 1999) . Such diverse actions of bepridil are probably responsible for the mechanism of prevention of arrhythmias, and further studies are required to distinguish between these mechanisms. However, it seems reasonable to conclude that bepridil is of advantage both in preventing ischemic damage and in management of ischemic arrhythmias.
